Put companies on watchlist
SCHOTT Pharma AG & Co. KGaA
ISIN: DE000A3ENQ51
WKN: A3ENQ5
Curious about what AI knows about SCHOTT Pharma? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

SCHOTT Pharma AG & Co. KGaA · ISIN: DE000A3ENQ51 · EQS - adhoc news (28 News)
Country: Germany · Primary market: Germany · EQS NID: 2115610
10 April 2025 06:15PM

SCHOTT Pharma: Preliminary Q2 2025 figures exceed capital market expectations 


EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Key word(s): Quarterly / Interim Statement/Quarter Results
SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma: Preliminary Q2 2025 figures exceed capital market expectations 

10-Apr-2025 / 18:15 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.


SCHOTT Pharma: Preliminary Q2 2025 figures exceed capital market expectations 

Based on preliminary figures, SCHOTT Pharma expects an increase in sales, EBITDA and EBITDA margin in the second quarter of 2025 (as of March 31, 2025). The company expects Q2 2025 revenues of EUR 252m, corresponding to a year-over-year growth of 10% at constant currencies. Accordingly, SCHOTT Pharma expects an EBITDA of EUR 72m and a corresponding EBITDA margin of 28.6%. 

These figures exceed the current market consensus of EUR 242m for revenues, 4% growth at constant currencies, EUR 62m EBITDA and a 25.5% EBITDA margin (source: Vara Research). 

SCHOTT Pharma maintains its full-year guidance for the fiscal year 2025 as published in December 2024.  

The company will publish its detailed figures for the second quarter and first half of 2025 on May 15, 2025. 
 

Investor contact
Tobias Erfurth
Head of Investor Relations
Jasko Terzic, CFA
Senior Investor Relations Manager
E-Mail: ir.pharma@schott.com

Press contact
Lea Kaiser
Communications Manager 
+49 (0) 6131/66-4073
E-Mail: lea.kaiser@schott.com



End of Inside Information

10-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SCHOTT Pharma AG & Co. KGaA
Hattenbergstraße 10
55122 Mainz
Germany
ISIN: DE000A3ENQ51
WKN: A3ENQ5
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
EQS News ID: 2115610

 
End of Announcement EQS News Service

2115610  10-Apr-2025 CET/CEST

Visual performance / price development - SCHOTT Pharma AG & Co. KGaA
Smart analysis and research tools can be found here.
MIC: XETR
Power-Shortcuts

SCHOTT Pharma AG & Co. KGaA

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.